Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study
ConclusionOccurrence of VTE in a total of 50,865 RA patients initiating treatment with tofacitinib or a TNF inhibitor was infrequent (<1 per 100 person ‐years). We observed a numerically higher, but statistically nonsignificant, risk of VTE in RA patients receiving tofacitinib versus those receiving TNF inhibitors.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Rishi J. Desai,
Ajinkya Pawar,
Michael E. Weinblatt,
Seoyoung C. Kim Tags: Brief Report Source Type: research
More News: Arthritis | Databases & Libraries | Insurance | Medicare | Pulmonary Thromboembolism | Rheumatoid Arthritis | Rheumatology | Statistics | Study | Thrombosis